Source: Nature Biotechnology, 32, 617–619, (2014), Published online 08 July 2014 Our good friends at Venture Valuation published an interesting study in the July issue of Nature Biotechnology. In…
Do you know which are the top branded drug products in India? We didn't until we found this handy chart and article. We took their IMS data a step…
We're actively seeking guest bloggers for LacertaBio.com! The ideal guest blogger: Is currently involved in business development and licensing Currently works for a pharma, biotech, VC, PE, or consultancy Is…
A quick search resulted in several recent examples of US-based pharma companies executing “inversions” to reduce taxes via the acquisition of companies in Ireland: Salix merges with Cosmo Technologies, the…
We're back and knee-deep in BIO2014 follow up work. Lacerta Bio was joined by 15,665 other "industry leaders" in days full of partnering discussions, pen-grabbing, eating and drinking, and…
An excellent analysis of the AstraZeneca pipeline performance was recently published in Nature Review. The objective of this study was to identify and assess key factors which drive R&D performance:…
This morning, Thompson Reuters and BIO presented a good webinar on preparing for BIO. I think it will be re-broadcast tomorrow. A lot of time was spent on characterising transactions…
Our friends at Pharmaphorum posted an overview of the recent WHO guidance for the treatment of hepatitis C. Of note, These new oral drugs are able to cure…
Much ink has already been spilled discussing the acquisition of Ranbaxy from Daiichi by Sun Pharma in an all stock transaction. A good analysis by a former Ranbaxy executive…
Yesterday, MannKind Corporation annouced that the FDA voted 13-1 in favor of an approval for Afrezza. You can find the press release here. We've Seen This Movie Before For…